Skip to main content
SpringerLink
Log in

Hereditary Colon Cancer: Lynch Syndrome

  • Chapter
  • First Online:
Principles of Clinical Cancer Genetics

Abstract

Colorectal cancer is the second leading cause of cancer-related deaths in the United States, with approximately 140,000 cases diagnosed and 50,000 deaths annually [1]. The majority of these cases are sporadic, occurring in individuals without any known familial predisposition. Approximately 10–30% of all colorectal cancer cases occur in the context of a family history [2], but most of the predisposing genetic factors have not yet been identified. Highly penetrant inherited colorectal cancer syndromes such as familial adenomatous polyposis (FAP), MYH-associated polyposis (MAP), and Lynch syndrome/hereditary nonpolyposis colon cancer (HNPCC) are less common but account for as many as 5% of colorectal cancer cases [3]. However, it is likely that this is an underestimate. With appropriate screening, an estimated 12,000 individuals could be diagnosed with Lynch syndrome on a yearly basis in the United States [4]. The ability to dramatically alter the clinical course of families with these syndromes mandates that clinicians understand the key features in the diagnosis and management of these hereditary colorectal cancer syndromes. Because of the absence of an overt polyposis phenotype, Lynch syndrome can be the most challenging hereditary colorectal syndrome to recognize.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Meyerhardt JA, Mayer RJ (2005) N Engl J Med 352:476–487

    Article  PubMed  CAS  Google Scholar 

  2. Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348:919–932

    Article  PubMed  CAS  Google Scholar 

  3. Smith RA, von Eschenbach AC, Wender R et al (2001) American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. CA Cancer J Clin 51:38–75

    Article  PubMed  CAS  Google Scholar 

  4. Hampel H, Frankel WL, Martin E et al (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26:5783–5788

    Article  PubMed  Google Scholar 

  5. Warthin AS (1925) The further study of a cancer family. J Cancer Res 9:279–286

    Google Scholar 

  6. Lynch HT, Krush AJ (1971) Cancer family G revisited: 1895–1970. Cancer 27:1505–1511

    Article  PubMed  CAS  Google Scholar 

  7. Jo WS, Chung DC (2005) Genetics of hereditary colorectal cancer. Sem Oncol 32:11–23

    Article  CAS  Google Scholar 

  8. Rijcken FE, Hollema H, Kleibeuker JH (2002) Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut 50:382–386

    Article  PubMed  CAS  Google Scholar 

  9. Vasen H, Wijnen J, Menko F et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020–1028

    Article  PubMed  CAS  Google Scholar 

  10. Watson P, Lynch H (2001) Cancer risk in mismatch repair gene mutation carriers. Fam Cancer 1:57–60

    Article  PubMed  CAS  Google Scholar 

  11. Hampel H, Stephens JA, Pukkala E et al (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129:415–421

    PubMed  Google Scholar 

  12. Chung DC, Rustgi AK (2003) The hereditary nonpolyposis colorectal cancer syndrome: genetic and clinical implications. Ann Intern Med 138:560–570

    PubMed  CAS  Google Scholar 

  13. Hendriks YMC, de Jong AE, Morreau H et al (2006) Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin 56:213–225

    Article  PubMed  Google Scholar 

  14. Vasen HF, Mecklin JP, Khan PM et al (1991) The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 34:424–425

    Article  PubMed  CAS  Google Scholar 

  15. Syngal S, Fox EA, Eng C et al (2000) Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 37:641–645

    Article  PubMed  CAS  Google Scholar 

  16. Liu T, Wahlberg S, Burek E et al (2000) Micro-satellite instability as a predictor of a mutation in a DNA mismatch repair gene in familial colorectal cancer. Genes Chromosomes Cancer 27:17–25

    Article  PubMed  CAS  Google Scholar 

  17. Lipton LR, Johnson V, Cummings C et al (2004) Refining the Amsterdam criteria and Bethesda guidelines: testing algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic. J Clin Oncol 22:4934–4943

    Article  PubMed  CAS  Google Scholar 

  18. Vasen HF, Watson P, Mecklin JP et al (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116:1453–1456

    Article  PubMed  CAS  Google Scholar 

  19. Hampel H, Frankel WL, Martin E et al (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352:1851–1860

    Article  PubMed  CAS  Google Scholar 

  20. Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268

    Article  PubMed  CAS  Google Scholar 

  21. Laghi L, Bianchi P, Malesci A (2008) Differences and evolution of the methods for the assessment of microsatellite instability. Oncogene 27(49):6313–6321

    Article  PubMed  CAS  Google Scholar 

  22. Gylling A, Ridanpaa M, Vierimaa O et al (2009) Large genomic rearrangements and germline epimutations in Lynch syndrome. Int J Cancer 124:2333–2340

    Article  PubMed  CAS  Google Scholar 

  23. Van der Klift H, Wijnen J, Wagner A et al (2005) Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC). Genes Chromosomes Cancer 44:123–138

    Article  PubMed  Google Scholar 

  24. Suter CM, Martin DIK, Ward RL (2004) Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet 36:497–501

    Article  PubMed  CAS  Google Scholar 

  25. Chan TL, Yuen ST, Kong CK et al (2006) Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet 38:1178–1183

    Article  PubMed  CAS  Google Scholar 

  26. Ligtenberg MJ, Kuiper RP, Chan TL et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41:112–117

    Article  PubMed  CAS  Google Scholar 

  27. Lindor NM, Burgart LJ, Leontovich O et al (2002) Immuno­histochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 20:1043–1048

    Article  PubMed  CAS  Google Scholar 

  28. Pinol V, Castells A, Andreu M et al (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293:1986–1994

    Article  PubMed  CAS  Google Scholar 

  29. Lindor NM, Petersen GM, Hadley DW et al (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296:1507–1517

    Article  PubMed  CAS  Google Scholar 

  30. Wahlberg SS, Schmeits J, Thomas G et al (2002) Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res 62:3485–3492

    PubMed  CAS  Google Scholar 

  31. Terdiman JP, Gum JR, Conrad PG et al (2001) Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germline genetic testing. Gastroenterology 120:21–30

    Article  PubMed  CAS  Google Scholar 

  32. Berends MJW, Wu Y, Sijmons RH et al (2002) Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet 70:26–37

    Article  PubMed  CAS  Google Scholar 

  33. Robinson KL, Liu T, Vandrovcova J et al (2007) Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst 99:291–299

    Article  CAS  Google Scholar 

  34. Pino MS, Mino-Kenudson M, Wildemore BM et al (2009) Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas. J Mol Diagn 11:238–247

    Article  PubMed  CAS  Google Scholar 

  35. Lindor NM, Rabe K, Petersen GM et al (2005) Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293(16):1979–1985

    Article  PubMed  CAS  Google Scholar 

  36. Deng G, Bell I, Crawley S et al (2004) BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1 but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10:191–195

    Article  PubMed  CAS  Google Scholar 

  37. Domingo E, Niessen RC, Oliveira C et al (2005) BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 24:3995–3998

    Article  PubMed  CAS  Google Scholar 

  38. Weisenberger DJ, Siegmund KD, Campan M et al (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38:787–793

    Article  PubMed  CAS  Google Scholar 

  39. Bessa X, Ballesté B, Andreu M et al (2008) A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol 6:206–214

    Article  PubMed  CAS  Google Scholar 

  40. Peltomaki P (2005) Lynch syndrome genes. Fam Cancer 4:227–232

    Article  PubMed  Google Scholar 

  41. Schofield L, Watson N, Grieu F et al (2009) Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J Cancer 124:1097–1102

    Article  PubMed  CAS  Google Scholar 

  42. Pouchet CJ, Wong N, Chong G et al (2009) A comparison of models used to predict MLH1, MSH2 and MSH6 mutation carriers. Ann Oncol 20:681–688

    Article  PubMed  CAS  Google Scholar 

  43. Green RC, Parfrey PS, Woods MO et al (2009) Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst 101:331–340

    Article  PubMed  Google Scholar 

  44. Kastrinos F, Stoffel EM, Balmana J et al (2008) Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1, 914 individuals undergoing clinical genetic testing in the United States. Cancer Epidemiol Biomarkers Prev 17:2044–2051

    Article  PubMed  CAS  Google Scholar 

  45. Goecke T, Schulmann K, Engel C et al (2006) Genotype–phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC consortium. J Clin Onc 24:4285–4292

    Article  CAS  Google Scholar 

  46. Watson P, Vasen HFA, Mecklin J-P et al (2008) The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 123:444–449

    Article  PubMed  CAS  Google Scholar 

  47. Kruse R, Rutten A, Lambert C et al (1998) Muir–Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet 63:63–70

    Article  PubMed  CAS  Google Scholar 

  48. Mangold J, Pagenstecher C, Leister M et al (2004) A genotype–phenotype correlation in HNPCC: strong predominance of MSH2 mutations in 41 patients with Muir–Torre syndrome. J Med Genet 41:567–572

    Article  PubMed  CAS  Google Scholar 

  49. Kruse R, Lamberti C, Wang Y et al (1996) Is the mismatch repair deficient type of Muir–Torre syndrome confined to mutations in the hMSH2 gene? Hum Genet 98:747–750

    Article  PubMed  CAS  Google Scholar 

  50. South CD, Hampel H, Comeras I et al (2008) The frequency of Muir–Torre syndrome among Lynch syndrome families. J Natl Cancer Inst 100:277–281

    Article  PubMed  CAS  Google Scholar 

  51. ten Kate GL, Kleibeuker JH, Nagengast FM et al (2007) Is surveillance of the small bowel indicated for Lynch syndrome families. Gut 56:1198–1201

    Article  PubMed  Google Scholar 

  52. Clyne M, Offman J, Shanley S et al (2009) The G67E mutation in hMLH1 is associated with an unusual presentation of Lynch syndrome. Br J Cancer 100:376–380

    Article  PubMed  CAS  Google Scholar 

  53. Nilbert M, Therkildsen C, Nissen A et al (2009). Sarcomas associated with hereditary nonpolyposis colorectal cancer: broad anatomical and morphological spectrum. Fam Cancer 8:209–213

    Article  PubMed  Google Scholar 

  54. Matthews KS, Estes JM, Conner MG et al (2008) Lynch syndrome in women less than 50 years of age with endometrial cancer. Obstet Gynecol 111:1161–1165

    Article  PubMed  Google Scholar 

  55. Hampel H, Frankel W, Panescu J et al (2006) Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66:7810–7817

    Article  PubMed  CAS  Google Scholar 

  56. Hendriks YMC, Jagmohan-Changur S, Van Der Klift HM et al (2006) Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome). Gastroenterology 130:312–322

    Article  PubMed  CAS  Google Scholar 

  57. Senter L, Clendenning M, Sotamaa K et al (2008) The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135:419–428

    Article  PubMed  CAS  Google Scholar 

  58. Niessen RC, Kleibeuker JH, Westers H et al (2009) PMS2 involvement in patients suspected of Lynch syndrome. Genes Chromosomes Cancer 48:322–329

    Article  PubMed  CAS  Google Scholar 

  59. Jarvinen HJ, Aarnio M, Mustonen H et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829–834

    Article  PubMed  CAS  Google Scholar 

  60. Schmeler KM, Lynch HT, Chen LM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261–269

    Article  PubMed  CAS  Google Scholar 

  61. Guillem JG, Wood WC, Moley JF et al (2006) ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 24:4642–4660

    Article  PubMed  Google Scholar 

  62. NCCN Practice Guidelines in Oncology – v.1.2009. Colorectal cancer screening, Hereditary predisposition, Lynch syndrome. CSCR-10

    Google Scholar 

  63. Dube C, Rostom A, Lewin G et al (2007) The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146:365

    PubMed  Google Scholar 

  64. Rostom A, Dube C, Lewin G et al (2007) Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146:376

    PubMed  Google Scholar 

  65. Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369:1603

    Article  PubMed  CAS  Google Scholar 

  66. Cruz-Correa M, Hylind LM, Romans KE et al (2002) Long-term treatment with Sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 122:641

    Article  PubMed  CAS  Google Scholar 

  67. Burn J, Bishop T, Mecklin J-P et al (2008) Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359:2567–2578

    Article  PubMed  CAS  Google Scholar 

  68. Gryfe R, Kim H, Hsieh ETK et al (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342:69–77

    Article  PubMed  CAS  Google Scholar 

  69. Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257

    Article  PubMed  CAS  Google Scholar 

  70. Jover R, Zapater P, Castells A et al (2006) Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55:848–855

    Article  PubMed  CAS  Google Scholar 

  71. Jo WS, Bandipalliam P, Shannon KM, Niendorf KB, Chan-Smutko G, Hur C, Syngal S, Chung DC (2005) Correlation of polyp number and family history of colon cancer with germline MYH mutations. Clin Gastroenterol Hepatol 3:1022–1028

    Article  PubMed  CAS  Google Scholar 

  72. Offit K, Kohut K, Clagett B et al (2006) Cancer genetic testing and assisted reproduction. J Clin Oncol 24:4775–4782

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA

    Eunice L. Kwak

  2. GI Cancer Genetics Program, Gastrointestinal Unit and Cancer Center Massachusetts General Hospital, Boston, MA, USA

    Daniel C. Chung

  3. Harvard Medical School, Boston, MA, USA

    Daniel C. Chung

Authors
  1. Eunice L. Kwak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel C. Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Eunice L. Kwak or Daniel C. Chung .

Editor information

Editors and Affiliations

  1. Cancer Center and Gastrointestinal Unit, Harvard Medical School, Massachusetts General Hospital, Boston, 02114, USA

    Daniel C. Chung

  2. Cancer Center, Harvard Medical School and, Massachusetts General Hospital, Boston, 02114, USA

    Daniel A. Haber

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Kwak, E.L., Chung, D.C. (2010). Hereditary Colon Cancer: Lynch Syndrome. In: Chung, D., Haber, D. (eds) Principles of Clinical Cancer Genetics. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-93846-2_6

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-93846-2_6

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-93844-8

  • Online ISBN: 978-0-387-93846-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation